Nanobiotix Files Routine 6-K Report

Ticker: NBTX · Form: 6-K · Filed: Mar 13, 2025 · CIK: 1760854

Sentiment: neutral

Topics: reporting, sec-filing, foreign-private-issuer

TL;DR

Nanobiotix filed a standard 6-K, no major news yet.

AI Summary

Nanobiotix S.A. filed a Form 6-K on March 13, 2025, to report its activities for the month of March 2025. The company, based in Paris, France, is a foreign private issuer and files annual reports under Form 20-F. This filing does not contain specific financial figures or operational updates beyond its routine reporting status.

Why It Matters

This filing indicates Nanobiotix is meeting its SEC reporting obligations as a foreign private issuer. Investors can monitor these filings for any material updates the company chooses to disclose.

Risk Assessment

Risk Level: low — This is a routine filing that does not contain new material information or financial data.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, have filed or are required to file with a stock exchange, or have distributed or are required to distribute to their security holders.

What is Nanobiotix S.A.'s primary business?

Nanobiotix S.A. is in the Pharmaceutical Preparations industry, SIC code 2834.

When is Nanobiotix S.A.'s fiscal year end?

Nanobiotix S.A.'s fiscal year ends on December 31.

Does this filing contain specific financial results for March 2025?

No, this Form 6-K is a report of foreign private issuer and does not appear to contain specific financial results for March 2025; it serves as a notification of reporting status.

What is the SEC file number for Nanobiotix S.A.?

The SEC file number for Nanobiotix S.A. is 001-39777.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on March 13, 2025 regarding Nanobiotix S.A. (NBTX).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing